



ANNEX 1

Response document for MHRA public consultation on the proposal to make Colourstart Test Patch available from general sales outlets without prescription

Ref: ARM 97

Your details

Name: [REDACTED]

Position (if applicable): Policy and Programmes Manager

Organisation (if applicable): Company Chemists' Association

Email:

1. Do you consider that Colourstart Test Patch should be available as a General Sale List (GSL) medicine?

Yes No Not sure

Please provide any comments or evidence to support your response:

We recognise the recommendations from the Commission on Human Medicines and are supportive of the decision to improve public access to Colourstart Test Patch by reclassification of this medicine from POM to GSL.

2. Do you have any specific comments on the leaflet or the label provided in the public reclassification report for Colourstart Test Patch?

Our only suggestion would be that the words DO NOT in the 'DO NOT use colourstart if you:...' list are coloured blue, as with the other headings, so as to draw further attention to this important list of contraindications.

3. Do you have any other comments on the reclassification?

No

4. The MHRA may publish consultation responses. Do you want your response to remain confidential?

Yes Partially* No

*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (reclassification@mhra.gov.uk) to arrive by **7 November 2018**. Contributions received after that date cannot be included in the exercise.